{"id":"vla1553","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the body's immune system to produce a protective response against SARS-CoV-2, the virus that causes COVID-19.","oneSentence":"VLA1553 is a COVID-19 vaccine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:46.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus"}]},"trialDetails":[{"nctId":"NCT07414524","phase":"","title":"VLA1553-403 Pregnancy Surveillance Study","status":"NOT_YET_RECRUITING","sponsor":"Valneva Austria GmbH","startDate":"2026-03-31","conditions":"Chikungunya Virus Infection","enrollment":200},{"nctId":"NCT07254702","phase":"","title":"Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil","status":"ENROLLING_BY_INVITATION","sponsor":"Valneva Austria GmbH","startDate":"2026-02-02","conditions":"Chikungunya Virus Infection","enrollment":5000},{"nctId":"NCT07163845","phase":"","title":"Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Valneva Austria GmbH","startDate":"2025-09-22","conditions":"Chikungunya Virus Infection","enrollment":5354},{"nctId":"NCT07347002","phase":"","title":"Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil","status":"ENROLLING_BY_INVITATION","sponsor":"Valneva Austria GmbH","startDate":"2026-02-02","conditions":"Chikungunya Virus Infection","enrollment":1200},{"nctId":"NCT07133178","phase":"PHASE3","title":"A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2026-02-06","conditions":"Chikungunya Virus Infection","enrollment":""},{"nctId":"NCT04838444","phase":"PHASE3","title":"Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Valneva Austria GmbH","startDate":"2021-04-02","conditions":"Chikungunya Virus Infection","enrollment":363},{"nctId":"NCT06106581","phase":"PHASE2","title":"A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2023-12-18","conditions":"Chikungunya Virus Infection","enrollment":304},{"nctId":"NCT06028841","phase":"PHASE3","title":"A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2024-04-10","conditions":"Chikungunya Virus Infection","enrollment":""},{"nctId":"NCT04650399","phase":"PHASE3","title":"A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2022-01-31","conditions":"Chikungunya","enrollment":750},{"nctId":"NCT04786444","phase":"PHASE3","title":"Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-02-22","conditions":"Chikungunya Virus Infection","enrollment":409},{"nctId":"NCT04546724","phase":"PHASE3","title":"Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2020-09-17","conditions":"Chikungunya Virus Infection","enrollment":4128},{"nctId":"NCT03382964","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2018-03-05","conditions":"Chikungunya","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VLA1553","genericName":"VLA1553","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"VLA1553 is a COVID-19 vaccine. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}